AI-powered small-molecule drug developer DeepCure has announced a chemical synthesis breakthrough in its proprietary Inspired Chemistry platform, which is designed to automatically synthesize thousands of complex molecules simultaneously, such as multiple chiral centers.
The platform is available to early access partners, enabling researchers to synthesize and test more diverse and complex molecule designs rapidly. A recent study has demonstrated the synthesizing of nirmatrelvir, an orally active 3C-like protease inhibitor, and 56 analogs parallelly in a robot-driven workflow. Key features of the product include AI-driven software for small-molecule design, the use of common laboratory instruments and robots, and the capacity to handle about 28 different reaction types currently.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.